Biocon shares rose over 2 per cent after Biocon Biologics' Japanese commercial partner launched Ustekinumab BS Subcutaneous ...

FDA biosimilar approvals reached a record 19 in 2024, with projections indicating that 2025 could surpass this milestone ...

Auto and Pharma indices are among the top gainers today. Nifty Pharma had declined about 1.3% in the last trading session.

The FDA originally approved Otulfi as a biosimilar in October 2024 based on clinical data that demonstrated the product was ...

President Donald Trump put the biopharma industry on its back foot earlier this month with his executive order on ...

A sweeping executive order signed by U.S. President Donald Trump to slash domestic drug prices has drawn fierce opposition ...

As per the company’s filing with the bourses, Biocon Biologics has developed and manufactured this injection while Yoshindo Inc.

Biocon had entered into a settlement and licensing agreement with Janssen Biotech Inc, Janssen Sciences Ireland and Johnson & ...

Feldman and Schor explain that the patent dance is a complex process to determine which of a biologic manufacturer’s patents ...

The U.S. Department of Health and Human Services (HHS) today announced immediate steps to implement President Trump’s ...

Drugmakers will be expected to commit to aligning U.S. prices with the lowest price set in a group of peer nations for all ...

Dr Reddys stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, ...